75 related articles for article (PubMed ID: 25242298)
1. Estimating and determining the effect of a therapy on tumor dynamics by means of a modified Gompertz diffusion process.
Albano G; Giorno V; Román-Román P; Román-Román S; Torres-Ruiz F
J Theor Biol; 2015 Jan; 364():206-19. PubMed ID: 25242298
[TBL] [Abstract][Full Text] [Related]
2. On the effect of a therapy able to modify both the growth rates in a Gompertz stochastic model.
Albano G; Giorno V; Román-Román P; Torres-Ruiz F
Math Biosci; 2013 Sep; 245(1):12-21. PubMed ID: 23347900
[TBL] [Abstract][Full Text] [Related]
3. Inferring the effect of therapies on tumor growth by using diffusion processes.
Román-Román P; Torres-Ruiz F
J Theor Biol; 2012 Dec; 314():34-56. PubMed ID: 22906590
[TBL] [Abstract][Full Text] [Related]
4. Inference on an heteroscedastic Gompertz tumor growth model.
Albano G; Giorno V; Román-Román P; Román-Román S; Serrano-Pérez JJ; Torres-Ruiz F
Math Biosci; 2020 Oct; 328():108428. PubMed ID: 32712317
[TBL] [Abstract][Full Text] [Related]
5. Modeling tumor growth in the presence of a therapy with an effect on rate growth and variability by means of a modified Gompertz diffusion process.
Román-Román P; Román-Román S; Serrano-Pérez JJ; Torres-Ruiz F
J Theor Biol; 2016 Oct; 407():1-17. PubMed ID: 27449789
[TBL] [Abstract][Full Text] [Related]
6. Inferring the effect of therapy on tumors showing stochastic Gompertzian growth.
Albano G; Giorno V; Román-Román P; Torres-Ruiz F
J Theor Biol; 2011 May; 276(1):67-77. PubMed ID: 21295592
[TBL] [Abstract][Full Text] [Related]
7. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():35-41. PubMed ID: 19032680
[TBL] [Abstract][Full Text] [Related]
8. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2337-42. PubMed ID: 18515579
[TBL] [Abstract][Full Text] [Related]
9. The role of RASSF1A in uveal melanoma.
Dratviman-Storobinsky O; Cohen Y; Frenkel S; Merhavi-Shoham E; El SD; Binkovsky N; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2012 Oct; 53(6):2611-9. PubMed ID: 22447862
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
[TBL] [Abstract][Full Text] [Related]
11. Uveal melanoma dormancy: an acceptable clinical endpoint?
Blanco PL; Lim LA; Miyamoto C; Burnier MN
Melanoma Res; 2012 Oct; 22(5):334-40. PubMed ID: 22895346
[TBL] [Abstract][Full Text] [Related]
12. Methods for subchoroidal implantation of Greene melanoma in rabbits.
Shikishima K
Int J Clin Oncol; 2004 Apr; 9(2):79-84. PubMed ID: 15108038
[TBL] [Abstract][Full Text] [Related]
13. Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis.
Notting IC; Buijs JT; Que I; Mintardjo RE; van der Horst G; Karperien M; Missotten GS; Jager MJ; Schalij-Delfos NE; Keunen JE; van der Pluijm G
Invest Ophthalmol Vis Sci; 2005 May; 46(5):1581-7. PubMed ID: 15851554
[TBL] [Abstract][Full Text] [Related]
14. The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma.
Rajaii F; Asnaghi L; Enke R; Merbs SL; Handa JT; Eberhart CG
Invest Ophthalmol Vis Sci; 2014 Aug; 55(10):6178-86. PubMed ID: 25146981
[TBL] [Abstract][Full Text] [Related]
15. Response of tumor spheroids to radiation: modeling and parameter estimation.
Bertuzzi A; Bruni C; Fasano A; Gandolfi A; Papa F; Sinisgalli C
Bull Math Biol; 2010 Jul; 72(5):1069-91. PubMed ID: 19915922
[TBL] [Abstract][Full Text] [Related]
16. A new Gompertz-type diffusion process with application to random growth.
Gutiérrez-Jáimez R; Román P; Romero D; Serrano JJ; Torres F
Math Biosci; 2007 Jul; 208(1):147-65. PubMed ID: 17275859
[TBL] [Abstract][Full Text] [Related]
17. [Selected prognostic factors of malignant uveal melanoma].
Svetlosáková Z; Krásnik V; Gergisáková H; Babál P; Kusenda P
Cesk Slov Oftalmol; 2012 Feb; 68(1):38-42. PubMed ID: 22679696
[TBL] [Abstract][Full Text] [Related]
18. Varying coefficient model with unknown within-subject covariance for analysis of tumor growth curves.
Krafty RT; Gimotty PA; Holtz D; Coukos G; Guo W
Biometrics; 2008 Dec; 64(4):1023-31. PubMed ID: 18261163
[TBL] [Abstract][Full Text] [Related]
19. [The pathological basis of the argument in the treatment of melanoma of the uveal tract].
Li YP
Zhonghua Yan Ke Za Zhi; 2012 Nov; 48(11):971-5. PubMed ID: 23302268
[TBL] [Abstract][Full Text] [Related]
20. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
